Skip to content
LIVE
WAR & GEOPOLITICS Air conditioning favored over emissions cuts in five European nations — 80% verified      SPORTS Birmingham City Women Return to WSL After Four Seasons — 80% verified      TOP STORIES British firm offers to restart Australian manganese smelter — 86% verified      WAR & GEOPOLITICS New diabetes and weight loss pill Foundayo launches in UK — 80% verified      SPORTS Newcastle’s energetic display against Liverpool analyzed by Match of the Day pundits — 80% verified      WAR & GEOPOLITICS Five arrested in CFMEU raid as Albanese pledges no GST change for WA — 80% verified      SPORTS Marc Guehi’s midfield shift praised by Joe Hart — 80% verified      TOP STORIES STXV.N stock price updates available on Reuters — 92% verified      ECONOMY & MARKETS Turning 70: Adjusting finances and lifestyle for richer retirement years — 64% verified      SPORTS Aston Villa’s ‘woeful’ defeat against Brighton analyzed — 80% verified      WAR & GEOPOLITICS Air conditioning favored over emissions cuts in five European nations — 80% verified      SPORTS Birmingham City Women Return to WSL After Four Seasons — 80% verified      TOP STORIES British firm offers to restart Australian manganese smelter — 86% verified      WAR & GEOPOLITICS New diabetes and weight loss pill Foundayo launches in UK — 80% verified      SPORTS Newcastle’s energetic display against Liverpool analyzed by Match of the Day pundits — 80% verified      WAR & GEOPOLITICS Five arrested in CFMEU raid as Albanese pledges no GST change for WA — 80% verified      SPORTS Marc Guehi’s midfield shift praised by Joe Hart — 80% verified      TOP STORIES STXV.N stock price updates available on Reuters — 92% verified      ECONOMY & MARKETS Turning 70: Adjusting finances and lifestyle for richer retirement years — 64% verified      SPORTS Aston Villa’s ‘woeful’ defeat against Brighton analyzed — 80% verified     
Monday, August 24, 2026
Updated 11 minutes ago
AI-Verified Global News Intelligence
AI MONITORING ACTIVE
4,825 articles published
War & Geopolitics 80% VERIFIED

New diabetes and weight loss pill Foundayo launches in UK

Foundayo, a daily pill for diabetes and weight loss, will be available in UK pharmacies, but officials warn of counterfeit risks.
War & Geopolitics · August 24, 2026 · 30 minutes ago · 2 min read · AI Summary · World news | The Guardian
80 / 100
AI Credibility Assessment
High Credibility
AI VERIFIED 0/3 claims verified 1 sources cited
Source Corroboration 30%
Source Tier Quality 70%
Claim Verification 40%
Source Recency 90%

Single-source rewrite; limited independent verification

A new daily pill called Foundayo that treats diabetes and aids in weight loss will be available in UK pharmacies starting Monday. The medication will be offered on private prescription, providing an alternative for those unable to use weight-loss injections. Pharmacists have welcomed the launch but also cautioned about the growing issue of counterfeit GLP-1 tablets in the market.

KEY FACTS

  • Foundayo, a daily pill for diabetes and weight loss, launches in UK pharmacies.
  • It will be available on private prescription starting Monday.
  • Pharmacists warn of counterfeit or unlicensed GLP-1 tablets in circulation.

What does Foundayo offer?

Foundayo provides an oral alternative to weight-loss injections, which some patients may find more convenient or preferable. The medication targets both diabetes management and weight loss, addressing two significant health concerns in one treatment. Its daily pill form could improve compliance for those who struggle with injectable medications.

What are the risks?

Pharmacists have raised concerns about counterfeit versions of GLP-1 tablets entering the market. These unregulated products may pose serious health risks, as their safety and efficacy are untested. The warning comes amid increasing demand for weight-loss treatments in the UK, creating opportunities for counterfeiters.

WHAT WE KNOW — AND WHAT WE DON’T

Verified by the source:

  • Foundayo will be available in UK pharmacies from Monday.
  • The medication requires a private prescription.
  • Pharmacists have issued warnings about counterfeit GLP-1 products.

Still unconfirmed:

  • The exact pricing structure for Foundayo.
  • Potential side effects specific to this medication.
  • Availability timeline outside the UK.

WHY IT MATTERS

With rising obesity and diabetes rates globally, effective treatments are in high demand. Foundayo’s dual-action approach could help many patients, but the counterfeit warning highlights the need for caution when seeking weight-loss medications. This development represents an important expansion of treatment options for UK patients.

WHAT TO WATCH

Patient adoption rates and any reported side effects will be important indicators of Foundayo’s success. Regulatory actions against counterfeit products may also intensify as this new medication enters the market.

Community Verdict — Do you trust this story?
Be the first to vote on this story.